ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

March 3, 2014 8:00 AM UTC

Anika Therapeutics Inc. (NASDAQ:ANIK) rose $11.43 (33%) to $45.90 on Wednesday after saying FDA approved Monovisc to treat osteoarthritis of the knee. Monovisc is a single injection that delivers hyaluronic acid from a non-animal source.

Partner Johnson & Johnson (NYSE:JNJ) will launch Monovisc in the U.S. this month...